Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biosimilarity of CHS-1701 vs Neulasta in Healthy Subjects
NCT02385851Phase 1Completed
- Sponsor
- Coherus BioSciences, Inc.
- Start
- Feb 2015
- Primary completion
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pegfilgrastim in neutropenia (2 arms), sponsored by Coherus BioSciences, Inc. Primary endpoint: Absolute Neutrophil Count at 84 Days. Started Feb 2015; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02385851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02385851.